EPRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.136

-41.78%

-0.160

-23.81%

-0.160

-38.46%

Estimates Revision

The market is revising No Change the revenue expectations for Eupraxia Pharmaceuticals Inc. (EPRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 33.77%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+33.77%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast EPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EPRX is 11.55 USD with a low forecast of 10.89 USD and a high forecast of 11.88 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

10.89

Averages

11.55

High

11.88

Current: 0.000

Low

10.89

Averages

11.55

High

11.88

H.C. Wainwright

Buy

maintain

$12

2025-08-20

Reason

H.C. Wainwright

Price Target

$12

2025-08-20

maintain

Buy

Reason

H.C. Wainwright believes Celldex's (CLDX) Phase 2 data for barzolvolimab in patients with eosinophilic esophagitis supports the positive thesis on Eupraxia Pharmaceuticals (EPRX). Barzolvolimab did not show improvements in eosinophilic esophagitis symptoms or endoscopic measures of disease activity compared to placebo, the analyst tells investors in a research note. The firm says a potential competitor to Eupraxia in eosinophilic esophagitis has been removed. The barzolvolimab study also validates the "simpler but more effective approach" Eupraxia is taking with EP-104GI, contends H.C. Wainwright. The firm has a Buy rating on the shares with a $12 price target.

Cantor Fitzgerald

NULL -> Overweight

initiated

$11

2025-07-24

Reason

Cantor Fitzgerald

Price Target

$11

2025-07-24

initiated

NULL -> Overweight

Reason

Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals with an Overweight rating and $11 price target.

H.C. Wainwright

NULL -> Buy

initiated

$12

2025-06-26

Reason

H.C. Wainwright

Price Target

$12

2025-06-26

initiated

NULL -> Buy

Reason

H.C. Wainwright initiated coverage of Eupraxia Pharmaceuticals with a Buy rating and $12 price target. Eupraxia has the potential for a best in class treatment for the "ever-growing" eosinophilic esophagitis market, the analyst tells investors in a research note. The firm says the company has shown the potential for an annual treatment of EP-104GI in this condition, which could grow to a 1M addressable patient market.

Canaccord

Speculative Buy

initiated

2025-06-17

Reason

Canaccord

Price Target

2025-06-17

initiated

Speculative Buy

Reason

Canaccord initiated coverage of Eupraxia Pharmaceuticals with a Speculative Buy rating and C$9 price target. In May 2024, the company shifted focus from knee osteoarthritis to eosinophilic esophagitis, a chronic, immune-mediated condition of the esophagus with rising prevalence and limited treatment options, the analyst tells investors in a research note. The firm says data from the ongoing Phase 1b/2a of Eupraxia's lead candidate, EP-104GI, suggest the product could offer "unprecedented durability and safety, potentially establishing it as a first-line treatment with annual dosing."

Valuation Metrics

The current forward P/E ratio for Eupraxia Pharmaceuticals Inc (EPRX.O) is -12.19, compared to its 5-year average forward P/E of -3.79. For a more detailed relative valuation and DCF analysis to assess Eupraxia Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.79

Current PE

-12.19

Overvalued PE

-0.79

Undervalued PE

-6.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.06

Current EV/EBITDA

-12.36

Overvalued EV/EBITDA

-0.14

Undervalued EV/EBITDA

-5.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

EPRX News & Events

Events Timeline

No data

News

9.0

01-08Benzinga

Eupraxia Pharmaceuticals Reports Significant Tissue Health Improvements in EoE Trial

9.0

01-08NASDAQ.COM

Eupraxia Pharmaceuticals Reports Positive 12-Week and 36-Week Data for EP-104GI in EoE Treatment

9.0

2025-11-13Newsfilter

Eupraxia Pharmaceuticals Shares New 52-Week Follow-Up Data from the RESOLVE Trial on Eosinophilic Esophagitis (EoE) Showing Consistent Outcomes with EP-104GI Treatment

People Also Watch

Frequently Asked Questions

What is Eupraxia Pharmaceuticals Inc (EPRX) stock price today?

The current price of EPRX is 8.12 USD — it has decreased -5.47 % in the last trading day.

What is Eupraxia Pharmaceuticals Inc (EPRX)'s business?

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.

What is the price predicton of EPRX Stock?

What is Eupraxia Pharmaceuticals Inc (EPRX)'s revenue for the last quarter?

Eupraxia Pharmaceuticals Inc revenue for the last quarter amounts to -6.52M USD, increased 12.42 % YoY.

What is Eupraxia Pharmaceuticals Inc (EPRX)'s earnings per share (EPS) for the last quarter?

Eupraxia Pharmaceuticals Inc. EPS for the last quarter amounts to -4566933.00 USD, decreased -55.37 % YoY.

What changes have occurred in the market's expectations for Eupraxia Pharmaceuticals Inc (EPRX)'s fundamentals?

How many employees does Eupraxia Pharmaceuticals Inc (EPRX). have?

Eupraxia Pharmaceuticals Inc (EPRX) has 33 emplpoyees as of January 10 2026.

What is Eupraxia Pharmaceuticals Inc (EPRX) market cap?

Today EPRX has the market capitalization of 411.26M USD.